ETCTN Trials by Disease/ Treatment Area: Breast Cancer

**Breast Cancer**

- Early stage TNBC
- Locally advanced/ metastatic TNBC
- Locally advanced/ metastatic ER+ and/or PR+/HER2
- Locally advanced/ metastatic ER+/HER2-
- Non HER2 positive with BRCA mutation
- PTEN or PIK3CB mutation (TNBC or ER+/HER2-)
- With residual cancer burden (TNBC or ER+ and/or PR+, HER2-BC)
- Expansion: Locally advanced/ metastatic HER2-
- Bone metastatic breast cancer (TNBC or ER+ and/or PR+)
- HER2+ PIK3CA mutation, PTEN mutation or PTEN loss

**Triple negative breast cancer (TNBC)**

- Early stage TNBC
- Locally advanced/ metastatic TNBC
- Locally advanced/ metastatic ER+ and/or PR+/HER2
- Locally advanced/ metastatic ER+/HER2-
- Non HER2 positive with BRCA mutation
- PTEN or PIK3CB mutation (TNBC or ER+/HER2-)
- With residual cancer burden (TNBC or ER+ and/or PR+, HER2-BC)
- Expansion: Locally advanced/ metastatic HER2-
- Bone metastatic breast cancer (TNBC or ER+ and/or PR+)
- HER2+ PIK3CA mutation, PTEN mutation or PTEN loss

**Hormone receptor positive (HR+)**

- Early stage TNBC
- Locally advanced/ metastatic ER+ and/or PR+/HER2
- Locally advanced/ metastatic ER+/HER2-
- Non HER2 positive with BRCA mutation
- PTEN or PIK3CB mutation (TNBC or ER+/HER2-)
- With residual cancer burden (TNBC or ER+ and/or PR+, HER2-BC)
- Expansion: Locally advanced/ metastatic HER2-
- Bone metastatic breast cancer (TNBC or ER+ and/or PR+)
- HER2+ PIK3CA mutation, PTEN mutation or PTEN loss

**HER2 positive**

- Early stage TNBC
- Locally advanced/ metastatic ER+ and/or PR+/HER2
- Locally advanced/ metastatic ER+/HER2-
- Non HER2 positive with BRCA mutation
- PTEN or PIK3CB mutation (TNBC or ER+/HER2-)
- With residual cancer burden (TNBC or ER+ and/or PR+, HER2-BC)
- Expansion: Locally advanced/ metastatic HER2-
- Bone metastatic breast cancer (TNBC or ER+ and/or PR+)
- HER2+ PIK3CA mutation, PTEN mutation or PTEN loss

**Breast Cancer**

- Early stage TNBC
- Locally advanced/ metastatic TNBC
- Locally advanced/ metastatic ER+ and/or PR+/HER2
- Locally advanced/ metastatic ER+/HER2-
- Non HER2 positive with BRCA mutation
- PTEN or PIK3CB mutation (TNBC or ER+/HER2-)
- With residual cancer burden (TNBC or ER+ and/or PR+, HER2-BC)
- Expansion: Locally advanced/ metastatic HER2-
- Bone metastatic breast cancer (TNBC or ER+ and/or PR+)
- HER2+ PIK3CA mutation, PTEN mutation or PTEN loss

**NOTE:** * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: August 23, 2019